Document Detail

Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
MedLine Citation:
PMID:  23299930     Owner:  NLM     Status:  MEDLINE    
CONCLUSION: Hypoxia induced by sustained sorafenib treatment confers sorafenib resistance to HCC through HIF-1α and NF-κB activation. EF24 overcomes sorafenib resistance through VHL-dependent HIF-1α degradation and NF-κB inactivation. EF24 in combination with sorafenib represents a promising strategy for HCC.
Yingjian Liang; Tongsen Zheng; Ruipeng Song; Jiabei Wang; Dalong Yin; Luoluo Wang; Haitao Liu; Lantian Tian; Xiang Fang; Xianzhi Meng; Hongchi Jiang; Jiaren Liu; Lianxin Liu
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2013-03-14
Journal Detail:
Title:  Hepatology (Baltimore, Md.)     Volume:  57     ISSN:  1527-3350     ISO Abbreviation:  Hepatology     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-04-23     Completed Date:  2013-07-05     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  8302946     Medline TA:  Hepatology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1847-57     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 American Association for the Study of Liver Diseases.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anoxia / physiopathology*
Antineoplastic Agents / pharmacology,  therapeutic use
Apoptosis / drug effects
Benzylidene Compounds / pharmacology*
Carcinoma, Hepatocellular / drug therapy*,  metabolism,  pathology
Cell Line, Tumor
Cell Movement / drug effects
Cell Survival / drug effects
Drug Resistance, Neoplasm / drug effects*
Drug Therapy, Combination
Hypoxia-Inducible Factor 1, alpha Subunit / antagonists & inhibitors*,  metabolism
Liver Neoplasms / drug therapy*,  metabolism,  pathology
Mice, Inbred BALB C
Mice, Nude
NF-kappa B / metabolism
Niacinamide / analogs & derivatives*,  pharmacology,  therapeutic use
Phenylurea Compounds / pharmacology,  therapeutic use*
Piperidones / pharmacology*
Treatment Outcome
Von Hippel-Lindau Tumor Suppressor Protein / metabolism*
Xenograft Model Antitumor Assays
Reg. No./Substance:
0/3,5-bis(2-fluorobenzylidene)piperidin-4-one; 0/Antineoplastic Agents; 0/Benzylidene Compounds; 0/HIF1A protein, human; 0/Hypoxia-Inducible Factor 1, alpha Subunit; 0/NF-kappa B; 0/Phenylurea Compounds; 0/Piperidones; 0/sorafenib; 25X51I8RD4/Niacinamide; EC Hippel-Lindau Tumor Suppressor Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The impact of recipient HLA-Cw and donor killer immunoglobulin-like receptor genotyping on the outco...
Next Document:  Mitochondrial targeting overcomes ABCA1-dependent resistance of lung carcinoma to ?-tocopheryl succi...